Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback